Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab
Non-Hodgkin's Lymphoma
About this trial
This is an interventional treatment trial for Non-Hodgkin's Lymphoma focused on measuring Lymphoma, Non-Hodgkin, Rituximab Refractory, Rituximab Failure, Indolent Non-Hodgkins Lymphoma
Eligibility Criteria
ELIGIBILITY: Key Inclusion Criteria Documented B-cell Non-Hodgkin's Lymphoma Small lymphocytic lymphoma (ALC < 5,000 cells/mm3) Marginal zone B-cell lymphoma (nodal, extranodal, or splenic types) Lymphoplasmacytic lymphoma Follicular center lymphoma, follicular Disease documented to be refractory to a full-course of the most recent rituximab therapy (single agent or combination) At least 1 prior chemotherapy regimen and maximum of 3 prior chemotherapy regimens Bidimensionally measurable disease (by CT scan) with at least one lesion measuring ≥ 2.0 cm in a single dimension Key Exclusion Criteria Patients who receive rituximab only as part of treatment with ibritumomab tiuxetan (Zevalin®) will not be eligible History of prior high dose chemotherapy with allogeneic stem cell support (history of autologous stem cell support is permissible)
Sites / Locations
- University of Alabama Birmingham
- Arizona Cancer Center
- Alta Bates Comprehensive Cancer Center
- Tower Hematology and Oncology Medical Group
- Moores UCSD Cancer Center
- USC/Norris Cancer Hospital
- Comprehensive Cancer Center - Desert Regional Medical Center
- Stanford University Division of Oncology
- University of Colorado Cancer Center
- Yale University School of Medicine
- Georgetown University Medical Center
- Rush University Medical Center
- Indiana Oncology Hematology Consultants, A Division of AHN
- Markey Cancer Center, University of Kentucky Medical Center
- LSU Health Sciences Center, Feist Weiller Cancer Center
- Dana Farber Cancer Institute
- University of Michigan Cancer Center
- Henry Ford Health System
- Washington University School of Medicine in St. Louis
- Nevada Cancer Institute
- University of New Mexico Cancer Research and Treatment Center
- Roswell Park Cancer Institute
- Weill Cornell Cancer Care Center
- Interlakes Foundation, Inc.
- University of Rochester Medical Center, James P. Wilmot Cancer Center
- Duke University School of Medicine
- The Cleveland Clinic Foundation Taussig Cancer Center
- The West Clinic/ACORN
- Sarah Cannon Research Institute
- Arlington Cancer Center
- University of Virginia Cancer Center
- University of Wisconsin
- Cross Cancer Institute
- British Columbia Cancer Agency
- Queen Elizabeth Health Sciences Centre
- Ottawa Hospital - General Campus
- Hopital Notre-Dame du CHUM
- Hopital du Sacre Couer de Montreal
- Saskatchewan Cancer Center Agency
- Hospital Espanol Auxilio Mutuo, Auxilio Mutuo Cancer Center
Arms of the Study
Arm 1
Experimental
1
bendamustine